Table 3.
Clinical trials of PARPi and cell cycle inhibitor administration in cancers
| NCT number | Intervention | Target | Disease setting | Phase | Trial status | Result |
|---|---|---|---|---|---|---|
| 04,149,145 | M4344 + Niraparib | ATRi + PARPi | PARPi-resistant recurrent ovarian cancer | I | Not yet recruiting | / |
| 04,655,183 | M4344 + Niraparib | ATRi + PARPi |
Advanced solid tumors Breast cancer with DDR mutations |
I/II | Withdrawn | / |
| 04,170,153 | M1774 + Niraparib | ATRi + PARPi | Metastatic or locally advanced Unresectable solid tumors | I | Recruiting | / |
| 02,723,864 |
VX-970 + Veliparib + Cisplatin |
ATRi + PARPi + Platinum |
Refractory solid tumors | I | Completed |
0/3;0/3;2/6;0/7;0/3;3/25;0/6 ORRs in each arms 1/3;2/3;5/6;4/7;3/3;10/25;3/6 DCRs in each arms |
| 04,267,939 | BAY1895344 + Niraparib | ATRi + PARPi |
Advanced solid tumors (excluding prostate cancer) Ovarian cancer |
Ib | Recruiting | / |
| 02,264,678 | AZD6738 + Olaparib | ATRi + PARPi | Advanced solid malignance—H&N SCC, ATM Pro/Def NSCLC, gastric, breast and ovarian cancer | I/II | Recruiting | / |
| 03,462,342 | AZD6738 + Olaparib | ATRi + PARPi | Recurrent ovarian cancer (platinum-sensitive or platinum-resistant cohort) | II | Recruiting | / |
| 04,065,269 | AZD6738 + Olaparib | ATRi + PARPi |
Relapsed ovarian (fallopian tube/primary peritoneal) and endometrial (uterus) clear cell carcinomas with/without loss of ARID1A expression Other rare relapsed gynecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status |
II | Recruiting | / |
| 03,682,289 | AZD6738 + Olaparib | ATRi + PARPi |
Clear cell/metastatic/stage III/IV renal cell carcinoma Locally advanced/metastatic/stage III/IV pancreatic cancer Locally advanced/metastatic malignant solid neoplasm Metastatic urothelial carcinoma |
II | Recruiting | / |
| 04,239,014 | AZD6738 + Olaparib | ATRi + PARPi | Ovarian cancer | II | Withdrawn | / |
| 04,090,567 | AZD6738 + Olaparib | ATRi + PARPi | Advanced or metastatic breast cancer with germline BRCA1/2 mutations | II | Recruiting | / |
| 02,937,818 | AZD6738 + Olaparib | ATRi + PARPi | Platinum refractory extensive-stage small-cell lung carcinoma | II | Active, not recruiting | / |
| 03,787,680 | AZD6738 + Olaparib | ATRi + PARPi |
Metastatic castration-resistant prostate cancer (mCRPC) with DNA repair proficiency (DRPro) mCRPC with DNA repair deficiency (DRDef) |
II | Active, not recruiting | / |
| 03,428,607 | AZD6738 + Olaparib | ATRi + PARPi | Relapsed small-cell lung cancer (SCLC) | II | Completed | / |
| 03,330,847 |
AZD6738 + Olaparib AZD1775 + Olaparib |
ATRi + PARPi WEE1i + PARPi |
Metastatic triple-negative breast cancer(TNBC) with BRC1/2 mutations Metastatic TNBC with other HRR gene mutations other than BRCA1/2 Metastatic TNBC without any mutation of HRR genes |
II | Active, not recruiting | / |
| 02,576,444 |
AZD6738 + Olaparib AZD1775 + Olaparib |
ATRi + PARPi WEE1i + PARPi |
Advanced solid tumors with mutations in homologous—DNA repair (HDR) genes or mutations such as ATM, CHK2, MRN (MRE11/NBS1/RAD50), CDKN2A/B and APOBEC Advanced solid tumors with mutations of TP53 or KRAS gene |
II | Active, Not Recruiting | / |
| 03,057,145 | Prexasertib + Olaparib | CHK1i + PARPi | Advanced solid tumors | I | Completed | / |
| 02,511,795 | AZD1775 + Olaparib | WEE1i + PARPi |
Refractory solid tumors Relapsed small-cell lung cancer (SCLC) |
Ib | Completed |
11.1% ORR in the total polulation; 55.7% DCR in the total population |
| 03,579,316 | AZD1775 + Olaparib | WEE1i + PARPi | PARPi-resistant recurrent ovarian (fallopian tube/primary peritoneal) cancers | II | Recruiting | / |